Previously Listed Funding

This is an accordion element with a series of buttons that open and close related content panels.

NIDDK FUNDING ANNOUNCEMENTS

Notice of Special Interest (NOSI): Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional) This NOSI encourages rigorous experimental designs, as well as the implementation of collaborative interdisciplinary research on the common causes and pathways of ill health and disease, differential risk, treatment outcomes, morbidity, and mortality across socioecological domains and levels of influence. Thoughtful incorporation of intersectionality and culturally and contextually relevant approaches into research by applying the NIMHD Minority Health and Health Disparities Research Framework to meet group- and population-level needs is encouraged. Partnership between early career and independent investigators, as well as experienced women’s health researchers with those with expertise in health disparities, are encouraged to strengthen and accelerate multidisciplinary research in this space. EXPIRED

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (observational studies) – This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. EXPIRED

NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement(clinical trials) – This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. A letter of intent is required 30 days prior to submission. EXPIRED

NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements  NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The activities required in the U34 will depend on the type of study (e.g., epidemiologic study, drug/device/biologics trial, behavior intervention). Because the purpose of the U34 is primarily for the conduct of administrative tasks needed to prepare for participant recruitment, activities involving human subjects will generally not be conducted during the U34 phase; however, brief activities involving interactions with individuals similar to those expected to participate in the full study during the U01 award may be allowed in order to aid in development of study procedures or operations (e.g., assessing usability of a form, device calibration, workflow optimization). As noted above, the U34 period may also include stakeholder engagement activities. The U34 is designed to: 1) permit early peer review of the rationale for the proposed clinical study; 2) permit assessment of the design and protocol of the proposed study; 3) provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. EXPIRED

NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) The NIDDK Catalyst Award is designed to complement NIDDK’s traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK’s Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. EXPIRED

Pilot Interventions to Integrate Social Care and Medical Care to Improve Health Equity (R01—Clinical Trial Required) This NIDDK Funding Opportunity Announcement will support pilot and feasibility trials to test interventions that involve screening for and addressing adverse social determinants of health (SDoH), also called social risks, during a health care visit. Patients’ endorsed social needs could be addressed by appropriately referring/navigating patients or caregivers to resources that address these issues at social service organizations located externally or co-located in the healthcare system. The trials will determine 1) feasibility and acceptability of screening for social risks, identifying social needs and implementing referral service linkages (e.g., addressing transportation and housing needs, food insecurity, etc.) within the context of a healthcare visit, and 2) preliminary signals of the intervention’s impact on both the social risk/need(s) and NIDDK disease outcomes. Preliminary data regarding intervention efficacy are not required. The proposed pilot and feasibility clinical trials should lay the foundation for larger clinical trials to integrate social care and medical care and improve health outcomes related to the prevention and/or treatment of diseases within the mission of NIDDK. It is expected that these pilot studies will begin to delineate promising practices for future equitable and effective “real world” implementation of social and medical care integration. The overarching goal of this FOA is to develop pragmatic approaches that can be used in health care settings to reduce health disparities in diseases within the mission of NIDDK and achieve health equity, especially among individuals from racial and ethnic minority groups, rural populations, sexual and gender minority groups, and other socioeconomically disadvantaged and medically underserved communities. EXPIRED

Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. Research Project data are expected to support one or more follow-on independent grant applications (e.g., R01s) submitted by Research Project Team investigators. The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Project Team to help ensure the research aims are met and to aid them in their successful integration into the broader urologic research field. The Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program. EXPIRED

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later stage therapeutics development and preclinical efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. Applicants are strongly encouraged to discuss research priorities with the Scientific Contacts for each division. The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called “therapeutic leads”) such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, identifying new therapeutic uses for existing compounds, or identifying mechanism of action for therapeutic leads. EXPIRED

Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required) This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required. EXPIRED

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs), including the NIDDK, based on their scientific missions. EXPIRED

Research Project Grant (Parent R01 Clinical Trial Required) The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators’ specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs), including the NIDDK. The R01 is the original, and historically the oldest, grant mechanism used by the NIH to support health-related research and development. All applications submitted to this Parent Funding Opportunity Announcement must propose clinical trial(s). Research grant applications are assigned to participating ICs based on receipt and referral guidelines and many applications are assigned to multiple participating ICs with related research interests. Applicants are encouraged to identify a participating IC that supports their area of research via the R01 Clinical Trial Required IC-Specific Scientific Interests and Contact website and contact Scientific/Research staff from relevant ICs to inquire about their interest in supporting the proposed research project. EXPIRED

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators’ specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs), including the NIDDK. The R01 is the original, and historically the oldest, grant mechanism used by the NIH to support health-related research and development. Research grant applications are assigned to participating ICs based on receipt and referral guidelines and applications may be assigned to multiple participating ICs with related research interests. Applicants are encouraged to identify a participating IC that supports their area of research via the R01 IC-Specific Scientific Interests and Contact website and contact Scientific/Research staff from relevant ICs to inquire about their interest in supporting the proposed research project. EXPIRED

Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional) The impact of pain on patient quality of life for diseases and conditions within the mission of the NIDDK is enormous. Despite prior research efforts, our understanding of the underlying biological and clinical contributors of pain remains limited. In addition, new clinical management strategies for pain that better measure, predict, and target pain and improve upon current interventions, such as opioids, are critically needed. The current Funding Opportunity Announcement will address these needs through the invitation of broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the NIDDK’s mission. Investigations are expected to provide important new insights into the pathophysiology and clinical features of pain and foster new and improved treatment and pain management strategies for patients. EXPIRED

Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed) Scientific discovery is often catalyzed by technological innovations. The kidney, urinary tract, blood, and blood-forming organs present unique technological challenges. To address these challenges, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to develop novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of kidney, urologic, or hematologic diseases. This Funding Opportunity Announcement (FOA) is intended to support tool or technology development projects, opening new areas of science or translational research. The projects supported by this FOA could involve proof-of-concept studies, prototyping, optimization of a technology for the unique anatomy or physiology of these organ systems, and refinement of technical specifications for subsequent deployment of the technology in laboratory or clinical settings. Applications submitted to this FOA should be highly innovative. These studies should break new ground or extend previous discoveries toward new directions or applications. Applications to this FOA should include projects distinct from those that can be supported through the traditional R01 grant mechanism. For example, long-term projects, or projects designed to increase knowledge in a well-established area, are not appropriate for this FOA. Posted 5/16/2020. Standard due dates. EXPIRED

Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data This Notice announces the availability of supplements to active grants which are intended to support collaborations that bring together expertise in biomedicine, data management, and artificial intelligence and machine learning (AI/ML) to make NIH-supported data useful and usable for AI/ML analytics. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at modernizing the biomedical research data ecosystem and making data FAIR (Findable, Accessible, Interoperable, and Reusable) with high impact for open science. For the purposes of this Notice, AI/ML is inclusive of machine learning (ML), deep learning (DL), and neural networks (NN). EXPIRED

Notice of Special Interest (NOSI): Administrative Supplements to Enhance Software Tools for Open Science This Notice announces the continuing availability of administrative supplements to active awards that have a significant software development component or key role in maintaining software tools of recognized value in biomedical and behavioral research. The goal of these supplements is to enhance the sustainability and impact of research software tools by enabling the use of best practices and design principles in software development and leverage advances in computing in a modern data ecosystem. The supplements are intended to support and encourage collaborations between scientists and software engineers to update, refactor and enhance the design, implementation, and cloud-readiness of research software and build new communities for open science. Through these awards, the NIH Office of Data Science Strategy (ODSS) intends to help researchers who have developed scientifically valuable software to make their tools robust and sustainable, take advantage of new data science, software engineering, and computing paradigms, reach a broader community and contribute to open science. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at building a better data infrastructure and a modernized data ecosystem. EXPIRED

Notice of Special Interest (NOSI): Administrative Supplements to Support the Exploration of Cloud in NIH-supported Research This notice announces the availability of supplemental funds from the Office of Data Science Strategy (ODSS) to NIH-managed or NIH-majority-funded projects that may benefit from using the cloud. The purpose of this announcement is to explore and test potential opportunities for leveraging cloud solutions to enhance existing NIH activities. Projects already using cloud may apply to explore and test cloud capabilities not yet leveraged. This initiative is aligned with the NIH Strategic Plan for Data Science, which describes actions aimed at building a better data infrastructure and a modernized data ecosystem. EXPIRED

NIDDK Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds (K26 – Independent Clinical Trial Not Allowed) The purpose of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds is to provide protected effort and resources to established, NIDDK-funded, mentors to provide high quality mentoring to graduate students and postdoctoral fellows from diverse backgrounds, including those from underrepresented groups (see, e.g., Notice of NIH’s Interest in Diversity). Program Directors/Principals Investigators (PD/PIs) (mentors) must be conducting research that falls within the missions of the NIDDK and such research programs should serve as the framework around which mentoring activities are constructed. PD/PIs/applicants must have a demonstrable track record of mentoring early career researchers from diverse backgrounds, including those from underrepresented groups. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. EXPIRED

Notice of Special Interest (NOSI): Addressing Health Disparities in NIDDK Diseases There are many diseases and disorders that disproportionately affect the health of underserved populations in the United States. African-Americans, Hispanic Americans, American Indians, Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, and rural populations experience much higher risks of and poorer health status than the majority population. Several of the diseases that disproportionately afflict underserved populations are high priority research areas for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The NIDDK seeks research to improve understanding of the causes of disparities in health and disability in the United States and reducing/eliminating health disparities directly related to the scientific areas within the mission of the NIDDK. The overall objective of this NOSI is to understand and mitigate health disparities in the development, diagnosis, and treatment of diseases of high priority to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It is recognized that both biologic and non-biologic factors may be operating in these underserved populations. Research approaches may include metabolic, genetic, genomic, proteomic, proteogenomics, behavioral, clinical and/or epidemiologic studies in representative populations. Advantage might be taken of extant cohort studies that have been established for investigation of diabetes or other diseases. Collaboration among investigators of these established cohorts would be desirable, so that these studies might jointly develop protocols and evaluate findings. Alternatively, investigators may propose to start a new cohort, appropriately powered, to capture the current risks and outcomes in the era of new medications for some of the diseases. Such studies of current risks might appropriately be based in large HMOs or clinical practices with structure and data management practices conducive to efficient and cost-effective analyses. EXPIRED

Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C-Clinical Trial Not Allowed) The purpose of this funding opportunity is to invite new Institutional Network Awards (U2C/TL1) to cultivate a highly integrated cohort of trainees and early career investigators and to develop career development resources to accelerate kidney, urologic, and hematologic research. To maximize integration and promote a true trainee community, Institutions are invited to submit a single, unified U2C/TL1 application to engage, recruit, prepare, and sustain the next generation of kidney, urology, and hematology researchers. Applications covering a single metropolitan area are strongly encouraged (see Section III.3). EXPIRED

Analysis, Technology, Leadership, Administration and Science (ATLAS) Center (U24 Clinical Trial Not Allowed) – RFA-DK-21-034. This Funding Opportunity Announcement intends to support the creation of an Analysis, Technology, Leadership, Administration and Science (ATLAS) Center that has the overarching goal of building the “go-to” open-access resource for the research community of mouse and human renal and genitourinary development and disease. The ATLAS Center will have scientific and administrative responsibilities including: 1) integrating and visualizing disparate datatypes and organs of the renal and genitourinary tract; 2) developing, adopting, or improving state-of-the-art computational tools and approaches to carry out analyses of multi-modal molecular and imaging data; 3) building interactive 2D/3D atlases and molecular maps with FAIR principles (findable, accessible, interoperable, and reusable) to promote data retrieval, exploration, discovery, and analysis by the community; 4) developing, designing, maintaining, and enhancing an open-access, interactive public data and analysis portal; and 5) coordinating internal and external activities of the GenitoUrinary Development Molecular Anatomy Project (GUDMAP) and (Re)Building a Kidney (RBK) consortia, including administration of an opportunity pool to address scientific gaps and opportunities. EXPIRED

Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed) The overall goal of the Fostering Research With Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the benign urologic research community. FORWARD Urology Centers will support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising junior investigators and/or researchers new to the field of benign urologic research. It is expected that the Research Project Team will generate data to support one or more follow-on independent grant applications (e.g., R01s). The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Team to help ensure the research aims are met and to aid them in their successful integration into the broader benign urologic research field. To facilitate these goals, the Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program. EXPIRED

Multidisciplinary K12 Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support institutional career development programs in urological research that will assist individuals with doctorate degrees (either clinical or professional) with an interest in benign urological disease or urological research to develop the skills necessary to initiate and sustain an independent research career in urological research. Research areas supported by this initiative must be related to the mission of the NIDDK (https://www.niddk.nih.gov/research-funding/research-programs#urologic-diseases). This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. Posted 6/6/2022. EXPIRED

OTHER NIH FUNDING ANNOUNCEMENTS

Notice of Special Interest (NOSI): Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional) The mission of the NIH is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The NIH is committed to supporting research that will increase scientific understanding of the health and well-being of various population and subpopulation groups and that will help to establish the effectiveness of evidence-based health interventions and services for individuals within these groups. NIH places high priority on research with populations that have distinct health risk profiles and who have also received insufficient attention from the scientific research enterprise. To this end, this Notice of Special Interest (NOSI) announces the availability of administrative supplements to provide funding for the expansion of existing research projects to incorporate sexual and gender minority (SGM) populations or SGM-relevant research questions. SGM populations include, but are not limited to, those populations described in NOT-OD-19-139. Basic, social, behavioral, clinical, translational, and health services research relevant to the missions of the sponsoring NIH Institutes or Centers (ICs) may be proposed in response to this solicitation. Potential applicants are encouraged to review the most recent annual Portfolio Analysis of NIH-funded SGM research to identify potential research gaps that may be relevant to this NOSI. More information about the SGM administrative supplements program and previously awarded research projects can be found on the SGMRO website. EXPIRED

Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional) The ComPASS Program is intended to make greater advances in promoting health and preventing disease among disproportionately impacted populations. ComPASS aims to be catalytic and cross-cutting in its integration of multisectoral partnerships, comprised of community organizations; local, state, Tribal, and federal governments; academic institutions and research organizations; and the private sector to address structural inequities that enable health disparities to persist. The program is transformative in its focus on structural health equity interventions given the evidenced impact of structural inequities on health outcomes. The ComPASS Program has two overall goals: 1) to catalyze, develop, and rigorously assess community-led, health equity structural interventions that leverage multisectoral partnerships to advance health equity; and 2) to develop a new health equity research model for community-led, multisectoral structural intervention research across NIH and other federal agencies. EXPIRED

Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed) The new funding opportunity will support cooperative agreement awards on tool and technology development as part of the HVP consortium. The goal of this initiative is to support the development of tools, models, and methods to address the technological and methodological challenges that are currently hindering robust interrogation into the constituents and functionality of the human virome. Current challenges include the heterogeneity of virome elements and the lack of universal viral molecular markers (analogous to bacterial 16S rRNA domains), sequencing errors that may lead to the false identification of viruses or variants, lack of standard references, difficulties working with low biomass samples, host and environmental DNA contamination, and inadequate bioinformatic tools for virome analysis. EXPIRED

Consortium Organization and Data Collaboration Center (CODCC) for the Human Virome Program (HVP) (U24 Clinical Trial Not Allowed) The new funding opportunity will support the HVP CODCC to serve as an organizational hub to provide support for administrative activities, promotion of research protocols and tool development, and assist data and biospecimen collection and harmonization. The CODCC will create and maintain a program data portal that will be an interactive dashboard and repository with visualization and search capabilities. The data portal will also serve as the access point for the Human Virome Catalog, a key resource that will be generated by the CODCC from the samples and datasets generated by the HVP consortium, as well as other external datasets that might be available. EXPIRED

Notice of Intent to Publish a Funding Opportunity for the NIH Common Fund Human Virome Program: Characterize the Human Virome in Longitudinal, Diverse Cohorts Across the Lifespan (U54 Clinical Trial Not Allowed) The new funding opportunity will support Virome Characterization Centers (VCCs) to join the HVP consortium. The goal of this initiative is to characterize the human virome and its dynamics by utilizing longitudinal, diverse human cohorts. This initiative aims to identify and characterize the viruses that comprise the human virome and provide an accurate estimate of its richness and complexity. At least six anatomic sites will be assessed by the HVP and include the blood; respiratory, gastrointestinal, and urogenital tracts (including urine/stool); oral cavity; central nervous system (CNS); skin. Other components, such as breast milk and tears, may also be examined. Responsive projects must aim to assess at least two or more of these anatomical sites, and the final coverage of all priority sites will be ensured programmatically before funding of awards. EXPIRED

Research Supplements to Promote Diversity in Health-Related Research – PA-21-071. NIH-wide announcement. Funds are available to program directors and principal investigators holding specific types of NIH research grants for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. Administrative supplements must support work within the scope of the original project. The application deadline varies by Institute or Center. This is an administrative supplement; clinical trial not allowed. EXPIRED

Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)  The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: (1) curriculum or methods development; (2) courses for skills development; and/or (3) research experiences. EXPIRED

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 – Clinical Trial Optional)  This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions. EXPIRED

Surgical Disparities Research (R01 – Clinical Trial Optional) National Institute on Minority Health and Health Disparities. The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level. EXPIRED

Neuromod Prize Competition The National Institutes of Health has launched the first phase of the Neuromod Prize(link is external), a $9.8 million competition to accelerate the development of neuromodulation therapies — targeted treatments that adjust nerve activity to improve organ function. The competition seeks scientists, engineers, and clinicians to submit novel concepts and clinical development plans to demonstrate solutions for precisely stimulating the peripheral nervous system to treat disease and improve human health. The first phase of the competition will award up to $800,000. NIH plans to launch a second phase awarding up to $4 million, and a third phase awarding up to $5 million, subject to the availability of funds. Details of the requirements and registration for phases 2 and 3 are expected to be announced at a future time. NIH is launching only phase 1 at this time. Phase 1 participants will submit concept papers describing their proposed therapeutic approaches and their plans for conducting proof-of-concept studies, rationales for therapeutic use, and expectations for clinical impact. EXPIRED

NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional); NIH Director’s New Innovator Award Program (DP2 Clinical Trial Optional) (early stage investigators) The awards support individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. Applicants must describe their innovative vision for addressing a major challenge or pursuing an outstanding opportunity of relevance to NIH, the importance of this challenge or opportunity, and your qualifications to engage in groundbreaking research within the application. No detailed scientific plan or specific aims should be provided since the research plan is expected to evolve during the tenure of he grant. EXPIRED

Notice of Special Interest: Alzheimer’s-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimer’s Disease The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD)—frontotemporal dementia, Lewy body dementia, Vascular Contributions to Cognitive Impairment and Dementia (VCID), and multiple etiology dementias—to allow the research to develop such a focus. Active awards with project end dates in FY 2024 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2023. Please note that a few ICs limit no-cost extensions in the final non-competing year of an award. For that reason, it is important to contact staff at the IC supporting the award when planning the request. As administrative supplements, the work proposed needs to be within the scope of the research or training that is already supported. Center awards and resource awards are most likely to be able to justify these supplements, as they tend to have a broad content scope. Some research grants will also qualify if the current research is on a related topic (such as cognitive decline in aging, caregiving, the biology of neurodegeneration, genetics, imaging, computational methods, pain perception, or biostatistical tools that have application to research on AD/ADRD). NIA hosts a website that provides details on how Alzheimer’s disease and its related dementias are defined and some examples of currently supported research. Awardees are expected to seek competing support to continue promising leads from the research supported through the supplement. Additional information on areas of interest and funding opportunity announcements can be found here: Funding Opportunities | National Institute on Aging (nih.gov). EXPIRED

OTHER FUNDING ANNOUNCEMENTS

2024 L’Oréal USA For Women in Science Fellowship on Trialect

• Award: Five fellowships, each with a grant of $60,000.
• Focus: Supporting women in Science and promoting their role as mentors for the next generation. Must be involved in basic research in the life and physical/material sciences, engineering & technology, computer science and mathematics.
• Eligibility: Open to U.S. citizens or permanent residents who have completed their PhD and are currently in a postdoctoral research position.
• For more information and to submit your application, please visit L’Oréal USA Grant. EXPIRED

Call for Pilot & Feasibility Proposals in Pediatric Kidney Disease – Pediatric Centers of Excellence in Nephrology The Pediatric Centers of Excellence in Nephrology (PCENs) at the University of Virginia (UVA),
Children’s Hospital of Philadelphia (CHOP), and Washington University in St. Louis (WashU) are issuing a joint RFA for Pilot and Feasibility (P&F) projects. The PCEN program is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, and was established to: (1) Attract new scientific expertise to the study of human pediatric kidney physiology, kidney development, and pediatric kidney disorders; (2) Encourage multidisciplinary research in these areas; and (3) Develop the pediatric nephrology research community—in part through the P&F Program.
The PCENs are seeking applications for one-year pilot and feasibility research projects. The maximum funding is $50,000 in direct costs for one year, with one optional no-cost extension (NCE). Applications are expected to generate preliminary data to support future research applications. Research with science proposed that is not relevant to pediatric kidney disease or health will not be accepted. Proposals that utilize one of the PCENs’ Cores are encouraged but not required (see descriptions below). Eligibility: Early-stage investigators, new investigators, or established investigators not previously involved in pediatric nephrology research are invited to apply. The P&F program and funds are not intended to support or supplement ongoing research of an established investigator. EXPIRED

Dent Disease Foundation Research Grant Program The Dent Disease Foundation seeks to support research that will ultimately lead to new diagnostics, treatments, and ultimately a cure for Dent Disease types 1 and 2. Applications for up to one to two years of support will be considered. These funds may be used in the following categories: Personnel, Supplies, other costs, and Equipment. Indirect costs of up to 10% of the direct costs (excluding equipment) may be requested. Maximum funding: $50,000 total, including Indirect costs. Dent disease foundation: www.dentdisease.org. EXPIRED

Pediatric Device Consortia Grants Program (P50) Clinical Trials Optional The intended goal of this FOA is to facilitate the development, production, and distribution of pediatric medical devices. Although the FOA is issued by the FDA’s Office of Orphan Products Development, the grant application is intended to encompass devices for all pediatric diseases and conditions, not just those that are rare. Applicants will request funding to serve as a nonprofit consortium to provide expert advising and support services to innovators of pediatric medical devices. The advising and services will focus on the total product life cycle for medical devices from concept, through pre-market development, to commercialization, and replacement by subsequent generations of devices. In addition, consortia should also provide expertise on evidence generation, including use of real-world evidence (RWE), for pediatric device development. As the consortia execute their mission, they are encouraged to collaborate with each other and the broader community and to maintain a commitment to health equity, diversity, and inclusion to foster innovation, development, and improve access to medical devices for all pediatric patients. Pediatric medical devices treat or diagnose diseases and conditions in individuals who are 21 years of age or younger (that is, up to but not including the 22nd birthday) at the time of diagnosis or treatment (21 CFR 814.3(s)). EXPIRED